when does semaglutide go off patent expires next year: Novo Nordisk faces tough competition in the Chinese obesity market With semaglutide's patent expiring, generics

medicine company

Retatrutide is still in clinical trials and isnt expected to become available for at least another six months

MedTech stocks continue to feel pressure from glucagon-like peptide-1 (GLP-1) drugs for obesity, based primarily on speculation, and despite strong third-quarter performances from many firms in this sector

Our full-spectrum obesity management programs can be up and running in weeks

This natural fluctuation reflects shifts in water retention, metabolism, hormonal cycles, and digestive timing rather than signaling treatment failure

That's why we offer CoolSculpting, a non-invasive and FDA-approved body contouring treatment